BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 20179216)

  • 1. Comparative profiling of the novel epothilone, sagopilone, in xenografts derived from primary non-small cell lung cancer.
    Hammer S; Sommer A; Fichtner I; Becker M; Rolff J; Merk J; Klar U; Hoffmann J
    Clin Cancer Res; 2010 Mar; 16(5):1452-65. PubMed ID: 20179216
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sagopilone, a microtubule stabilizer for the potential treatment of cancer.
    Galmarini CM
    Curr Opin Investig Drugs; 2009 Dec; 10(12):1359-71. PubMed ID: 19943207
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved cellular pharmacokinetics and pharmacodynamics underlie the wide anticancer activity of sagopilone.
    Hoffmann J; Vitale I; Buchmann B; Galluzzi L; Schwede W; Senovilla L; Skuballa W; Vivet S; Lichtner RB; Vicencio JM; Panaretakis T; Siemeister G; Lage H; Nanty L; Hammer S; Mittelstaedt K; Winsel S; Eschenbrenner J; Castedo M; Demarche C; Klar U; Kroemer G
    Cancer Res; 2008 Jul; 68(13):5301-8. PubMed ID: 18593931
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective, multicenter, randomized, independent-group, open-label phase II study to investigate the efficacy and safety of three regimens with two doses of sagopilone as second-line therapy in patients with stage IIIB or IV non-small-cell lung cancer.
    Heigener DF; von Pawel J; Eschbach C; Brune A; Schmittel A; Schmelter T; Reck M; Fischer JR
    Lung Cancer; 2013 Jun; 80(3):319-25. PubMed ID: 23522488
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient-derived xenografts of non-small-cell lung cancer: a pre-clinical model to evaluate adjuvant chemotherapy?
    Merk J; Rolff J; Becker M; Leschber G; Fichtner I
    Eur J Cardiothorac Surg; 2009 Sep; 36(3):454-9. PubMed ID: 19502076
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemoresistance in non-small-cell lung cancer: can multidrug resistance markers predict the response of xenograft lung cancer models to chemotherapy?
    Merk J; Rolff J; Dorn C; Leschber G; Fichtner I
    Eur J Cardiothorac Surg; 2011 Jul; 40(1):e29-33. PubMed ID: 21420313
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study evaluating the efficacy and safety of sagopilone (ZK-EPO) in patients with metastatic breast cancer that has progressed following chemotherapy.
    Morrow PK; Divers S; Provencher L; Luoh SW; Petrella TM; Giurescu M; Schmelter T; Wang Y; Hortobagyi GN; Vahdat LT
    Breast Cancer Res Treat; 2010 Oct; 123(3):837-42. PubMed ID: 20697802
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular mode of action and role of TP53 in the sensitivity to the novel epothilone sagopilone (ZK-EPO) in A549 non-small cell lung cancer cells.
    Winsel S; Sommer A; Eschenbrenner J; Mittelstaedt K; Klar U; Hammer S; Hoffmann J
    PLoS One; 2011 Apr; 6(4):e19273. PubMed ID: 21559393
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical relevance of human cancer xenografts as a tool for preclinical assessment: example of in-vivo evaluation of topotecan-based chemotherapy in a panel of human small-cell lung cancer xenografts.
    Némati F; Daniel C; Arvelo F; Legrier ME; Froget B; Livartowski A; Assayag F; Bourgeois Y; Poupon MF; Decaudin D
    Anticancer Drugs; 2010 Jan; 21(1):25-32. PubMed ID: 19823076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The modifier subunit of glutamate cysteine ligase relates to cisplatin resistance in human small cell lung cancer xenografts in vivo.
    Nishi M; Abe Y; Fujimori S; Hamamoto A; Inoue Y; Miyazaki N; Oida Y; Ikoma N; Ohnishi Y; Yamazaki H; Ueyama Y; Nakamura M
    Oncol Rep; 2005 Aug; 14(2):421-4. PubMed ID: 16012725
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epothilones in prostate cancer.
    Kelly WK
    Urol Oncol; 2011; 29(4):358-65. PubMed ID: 19914096
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer.
    Blumenschein GR; Gatzemeier U; Fossella F; Stewart DJ; Cupit L; Cihon F; O'Leary J; Reck M
    J Clin Oncol; 2009 Sep; 27(26):4274-80. PubMed ID: 19652055
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of betaIII tubulin in predicting chemoresistance in non-small cell lung cancer.
    Sève P; Reiman T; Dumontet C
    Lung Cancer; 2010 Feb; 67(2):136-43. PubMed ID: 19828208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical discovery of ixabepilone, a highly active antineoplastic agent.
    Lee FY; Borzilleri R; Fairchild CR; Kamath A; Smykla R; Kramer R; Vite G
    Cancer Chemother Pharmacol; 2008 Dec; 63(1):157-66. PubMed ID: 18347795
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical efficacy of vascular disrupting agents in non-small-cell lung cancer.
    Baguley BC
    Clin Lung Cancer; 2011 Mar; 12(2):81-6. PubMed ID: 21550553
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sagopilone crosses the blood-brain barrier in vivo to inhibit brain tumor growth and metastases.
    Hoffmann J; Fichtner I; Lemm M; Lienau P; Hess-Stumpp H; Rotgeri A; Hofmann B; Klar U
    Neuro Oncol; 2009 Apr; 11(2):158-66. PubMed ID: 18780814
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antagonism of platelet-derived growth factor receptor in non small cell lung cancer: rationale and investigations.
    Bauman JE; Eaton KD; Martins RG
    Clin Cancer Res; 2007 Aug; 13(15 Pt 2):s4632-6. PubMed ID: 17671155
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib.
    Valabrega G; Capellero S; Cavalloni G; Zaccarello G; Petrelli A; Migliardi G; Milani A; Peraldo-Neia C; Gammaitoni L; Sapino A; Pecchioni C; Moggio A; Giordano S; Aglietta M; Montemurro F
    Breast Cancer Res Treat; 2011 Nov; 130(1):29-40. PubMed ID: 21153051
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The subunits of glutamate cysteine ligase enhance cisplatin resistance in human non-small cell lung cancer xenografts in vivo.
    Fujimori S; Abe Y; Nishi M; Hamamoto A; Inoue Y; Ohnishi Y; Nishime C; Matsumoto H; Yamazaki H; Kijima H; Ueyama Y; Inoue H; Nakamura M
    Int J Oncol; 2004 Aug; 25(2):413-8. PubMed ID: 15254739
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical efficacy spectrum and pharmacokinetics of ixabepilone.
    Lee FY; Smykla R; Johnston K; Menard K; McGlinchey K; Peterson RW; Wiebesiek A; Vite G; Fairchild CR; Kramer R
    Cancer Chemother Pharmacol; 2009 Jan; 63(2):201-12. PubMed ID: 18350296
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.